Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

CHRS - Coherus BioSciences, Inc.

IEX Last Trade
1.465
-0.010   -0.683%

Share volume: 14,533
Last Updated: Thu 26 Dec 2024 08:29:47 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%
$1.48
-0.01
-0.68%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
16%
Profitability 25%
Dept financing 25%
Liquidity 31%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
2.80%
1 Month
14.84%
3 Months
38.68%
6 Months
-11.45%
1 Year
-32.57%
2 Year
-74.17%
Key data
Stock price
$1.46
P/E Ratio 
-5.46
DAY RANGE
$1.41 - $1.48
EPS 
-$0.26
52 WEEK RANGE
$0.73 - $3.70
52 WEEK CHANGE
-$54.63
MARKET CAP 
160.140 M
YIELD 
N/A
SHARES OUTSTANDING 
115.209 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
BETA 
2.59
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,887,243
AVERAGE 30 VOLUME 
$9,752,054
Company detail
CEO: Denny M. Lanfear
Region: US
Website: coherus.com
Employees: 330
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Coherus BioSciences, Inc. markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor. Pipeline products include biosimilars of Humira, Avastin, and Lucentis. Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China.

Recent news